1. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Issue 10183 (4th May 2019) Authors: Mok, Tony S K; Wu, Yi-Long; Kudaba, Iveta; Kowalski, Dariusz M; Cho, Byoung Chul; Turna, Hande Z; Castro, Gilberto; Srimuninnimit, Vichien; Laktionov, Konstantin K; Bondarenko, Igor; Kubota, Kaoru; Lubiniecki, Gregory M; Zhang, Jin; Kush, Debra; Lopes, Gilberto Journal: Lancet Issue: Volume 393:Issue 10183(2019) Page Start: 1819 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗